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Warts and squamous cell carcinomas are important
cutaneous complications in organ transplant recipi-
ents. The role of infection with human papilloma-
viruses (HPV) in the development of cutaneous
squamous cell carcinoma is still unclear. An extre-
mely diverse group of HPV types, mainly consisting
of epidermodysplasia-verruciformis (EV)-associated
HPV types, can be detected in benign, premalignant,
and malignant skin lesions of organ transplant recipi-
ents. Frequently, there are multiple HPV types
present in single skin biopsies. Typically, the preva-
lence of viral warts rises steadily after transplantation
and a strong association exists between the number
of HPV-induced warts and the development of skin
cancer. The interval between the transplantation to
the development of warts is clearly shorter than the
interval from transplantation to the diagnosis of the
®rst skin cancer. A comparison of transplant recipi-
ents with and without skin cancer, however, showed
an equally high prevalence of EV-HPV DNA in kera-
totic skin lesions in both groups of patients and the
detection rate and spectrum of HPV infection in
hyperkeratotic papillomas, actinic keratoses, and
squamous cell carcinomas was also similar. HPV
DNA can frequently be detected in patients with
hyperproliferative disorders like psoriasis and anti-
bodies against HPV in patients with regenerating
skin (e.g., after extensive second degree burns).
Latent infection with EV-HPV seems to be wide-
spread. The hair follicle region might be the reser-
voir of EV-HPV. The E6 protein from a range of
cutaneous HPV types effectively inhibits apoptosis in
response to UV-light induced damage. It is therefore
conceivable that individuals who are infected by
EV-HPV are at an increased risk of developing acti-
nic keratoses and squamous cell carcinomas, possibly
by chronically preventing UV-light induced apopto-
sis. Key words: basal cell carcinoma/epidermodysplasia
verruciformis/squamous cell carcinoma/UV light. Journal of
Investigative Dermatology Symposium Proceedings 6:207±
211, 2001
Risk of skin cancer in the immunocompetent
population Skin cancers are the most common malignant
tumors among the Caucasian population. Cutaneous squamous cell
carcinoma and basal cell carcinoma, together commonly called
nonmelanoma skin cancers, account for almost 90% of cutaneous
malignancies (Harvey et al, 1989; Goldberg, 1996; Marks, 1996).
Although the annual mortality rate from nonmelanoma skin cancers
is relatively low, due to the high prevalence and substantial degree
of morbidity, these tumors present a signi®cant and costly health
problem (Preston and Stern, 1992). Exposure to sunlight is
generally considered to be the most important risk factor for
nonmelanoma skin cancers (Brash et al, 1991; Marks, 1996).
Infection with human papillomaviruses (HPV), however, may also
be important, especially for the development of squamous cell
carcinomas (P®ster and ter Schegget, 1997).
Risk of warts and skin cancer in organ transplant recipients
Warts and squamous cell carcinomas are by far the most important
cutaneous clinical problem in organ transplant recipients (Boyle et
al, 1984; Barr et al, 1989; Hartevelt et al, 1990; Bouwes Bavinck et
al, 1991; Glover et al, 1994; Hardie, 1995). In organ transplant
recipients the most important risk factor for skin cancer is the
immunosuppressive therapy.
Like in the immunocompetent population, exposure to sunlight
is believed to be a major risk factor for the development of
nonmelanoma skin cancer in organ transplant recipients. In
countries with low exposure to sunlight, the cumulative incidence
of skin cancer is 10% 10 y after the transplantation and 40% 20 y
after the transplantation (Birkeland et al, 1995; Hartevelt et al, 1990;
London et al, 1995). In Australia, Spain, and the U.S.A., these
numbers are even much higher, namely 40% and 70% after 10 and
20 y, respectively (Hardie et al, 1980; FerraÂndiz et al, 1995; Bouwes
Bavinck et al, 1996; Lampros et al, 1998). Many patients develop 10
to more than 100 skin cancers in short time periods.
The role of infection with human papillomaviruses in the
development of cutaneous squamous cell carcinoma is still unclear.
This review focuses on the role of HPV infection in the
development of skin cancer in organ transplant recipients and
draws a parallel with the development of cervical cancer in HPV16-
infected women.
Postulates for an oncogenic role of HPV infection
Prerequisites for a role of HPV infection in the pathogenesis of
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cervix carcinoma are (i) that the viral DNA can be detected in the
majority of the carcinomas (preferably in high copy numbers), (ii)
that the viral genes (most notably the oncogenes) are expressed in
the tumor cells, and (iii) that the viral genome persists during
metastatic spread of the tumor cells or passage of the cells in vitro
(P®ster and ter Schegget, 1997; Walboomers et al, 1999; zur
Hausen, 2000). This is in contrast to a large series of rather
frustrating attempts to demonstrate HPV-DNA in nonmelanoma
skin cancers by conventional nucleic acid hybridization techniques
(P®ster and ter Schegget, 1997). When discussing a possible role of
HPV in skin cancer, one should therefore be prepared to
acknowledge a more indirect and maybe transient effect of HPV
on the pathogenesis of skin cancer (P®ster and ter Schegget, 1997).
Arguments in favor of and against a possible role of HPV infection
in relation to skin cancer are discussed later in this review.
HPV16 INFECTION AND THE RISK OF CERVICAL
CARCINOMA
Risk of cervical carcinoma in the immunocompetent
population During the past 20 y, several types of HPV have
been identi®ed that cause speci®c types of cancers (zur Hausen,
2000). High-risk HPV types like HPV16 are a necessary cause of
squamous cell carcinoma of the cervix (Walboomers et al, 1999).
These tumors are characterized by the presence of mostly integrated
HPV DNA in all tumor cells. Viral oncogene expression (E6 and
E7) can be demonstrated in tumor material. Furthermore, extensive
evidence has been presented for an important role of these high-risk
HPV types in the pathogenesis of cervical cancer (zur Hausen,
2000). Transforming properties of the E6/E7 genes have been
identi®ed. E6 and E7 expression is required for maintaining the
malignant phenotype of cervical carcinoma cell lines and both
oncoproteins interact with growth-regulating host-cell proteins.
Finally, epidemiologic studies identi®ed these HPV infections as a
risk factor for the development of cervical cancer (zur Hausen,
2000).
Risk of anogenital warts and cervical carcinoma in organ
transplant recipients A number of studies have been
conducted to estimate the prevalence of anogenital and cervical
lesions among groups of women who are immunosuppressed
following organ transplantation (Schneider et al, 1983; Alloub et al,
1989; Kelly et al, 1991; IARC, 1995; Euvrard et al, 1996). In an
Australian cohort of transplant recipients a standardized incidence
ratio for cervical cancer of 3.3 was calculated compared with the
normal population (Fairley et al, 1994), and in a Nordic cohort a
standardized incidence ratio of 8.6 was found (Birkeland et al,
1995).
EPIDEMIOLOGY OF CUTANEOUS HPV INFECTION IN
ORGAN TRANSPLANT RECIPIENTS
High incidence of warts and skin cancer Many organ
transplant recipients have a highly increased incidence of both viral
warts and squamous cell carcinoma, and DNA of human
papillomaviruses can frequently be detected in nonmelanoma skin
cancers, raising the question of a possible causal contribution of
these viruses to skin carcinogenesis (Boyle et al, 1984; Penn and
Brunson, 1988; Bouwes Bavinck et al, 1991, 1998; Bouwes
Bavinck et al, 1994; Bouwes Bavinck and Berkhout, 1997; P®ster
and ter Schegget, 1997; Harwood et al, 1999a, 2000; Jensen et al,
1999; Wieland et al, 2000). Sooner or later after the transplantation,
almost all patients will experience warts.
A diverse group of HPV types can be detected An
extremely diverse group of HPV types consisting of
epidermodysplasia-verruciformis (EV)-associated HPV types (e.g.,
EV-HPV types of subgroup A: HPV5, 8, 12, 14, 19, 20, 21, 25, 36,
and 47, EV-HPV types of subgroup B: HPV9, 15, 17, 22, 23, 37,
38, and 47, and EV-HPV types of subgroup C: HPV24) (Berkhout
et al, 2000) and other cutaneous HPV types (e.g., HPV2, 3, 10, 27,
28, 29, and 58), as well as dozens of putatively new EV and
cutaneous HPV types, can be detected in benign, premalignant, and
malignant skin lesions of organ transplant recipients. The EV-HPV
types prevail in all lesion types (Soler et al, 1993; Tieben et al, 1993,
1994; Berkhout et al, 1995, 2000; de Jong-Tieben et al, 1995, 2000;
McGregor and Proby, 1996; Shamanin et al, 1996; Arends and
Benton, 1997; de Villiers et al, 1997; HoÈp¯ et al, 1997; Bens et al,
1998; Harwood et al, 1998, 2000; Forslund et al, 1999).
Multiple HPV types can be found in single lesions
Frequently, there are multiple HPV types present in single skin
biopsy specimens of organ transplant recipients (Berkhout et al,
2000; Harwood et al, 2000). An approach with PCR techniques for
the detection of distinct (sub)groups of genotypically related
cutaneous HPV types, i.e., three subgroups of EV-associated
HPV types and two groups of other cutaneous HPV types,
generally allows a reliable identi®cation of HPV genotypes by
direct sequencing of the PCR products, despite the frequent
occurrence of multiple infections (Berkhout et al, 2000).
The frequency of EV-associated HPV and other cutaneous HPV
types is similar in biopsy specimens from hyperkeratotic papillomas
(78%), actinic keratoses (68%), and squamous cell carcinomas
(78%), but appears to be lower in specimens of basal cell carcinomas
(36%), benign skin lesions (39%), and clinically normal skin (32%)
(Berkhout et al, 2000) (Fig 1). Similar prevalence rates were found
in another study in which HPV DNA was detected in 84% of
squamous cell carcinomas and 88% of premalignant skin lesions
(Harwood et al, 2000). The prevalence rate of 75% in basal cell
carcinomas, however, was much higher in this study (Harwood et
al, 2000).
Latent infection with EV-HPV seems to be widespread. The hair
follicle region might be the reservoir of EV-HPV (Boxman et al,
1997, 1999a, b).
ARGUMENTS IN FAVOR OF A ROLE OF EV-HPV
INFECTION IN SKIN CANCER ONCOGENESIS
The earliest evidence that HPV infection may play a role in skin
cancer oncogenesis comes from studies in patients with the rare
hereditary syndrome epidermodysplasia verruciformis (EV) (Orth,
1987). EV patients acquire characteristic skin warts during child-
hood and one-third of these patients develop squamous cell
carcinomas on sun-exposed skin at young age (Orth, 1987). The
HPV types found in the skin lesions of these patients by Southern
blot hybridization are commonly referred to EV HPV types and
include HPV5, 8, 9, 12, 14, 15, 19±25, 36, 38, and 47 (P®ster and
ter Schegget, 1997).
There are several arguments supporting a causative role of HPV
infection in the development of squamous cell carcinomas in organ
transplant recipients. The prevalence of viral warts rises steadily
after transplantation (Gassenmaier et al, 1986; RuÈdlinger et al, 1986;
van der Leest et al, 1987; Barr et al, 1989; Dyall-Smith et al, 1991;
de Jong-Tieben et al, 2000). The interval between the transplan-
tation to the development of warts is clearly shorter than the
interval from transplantation to the diagnosis of the ®rst skin cancer
(Bouwes Bavinck et al, 1993; de Jong-Tieben et al, 2000) and a
strong association exists within organ transplant recipients between
the number of HPV-induced warts and the development of skin
cancer (Fig 2) (Bouwes Bavinck et al, 1991; Bouwes Bavinck et al,
1993; de Jong-Tieben et al, 2000).
In addition, DNA of the epidermodysplasia-verruciformis asso-
ciated subgroup of HPV (EV-HPV) can frequently be detected in
biopsies of premalignant lesions and nonmelanoma skin cancers of
organ transplant recipients (de Jong-Tieben et al, 1995, 2000;
Harwood et al, 1999b, 2000) and EV-HPV infection in organ-
transplant recipients may persist for many years, suggesting that
organ transplant recipients are prone to persistent cutaneous HPV
infection (Berkhout et al, 2000; de Jong-Tieben et al, 2000).
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ARGUMENTS AGAINST A ROLE OF EV-HPV
INFECTION IN SKIN CANCER ONCOGENESIS
There are several arguments against a direct causative role of EV-
HPV infection in skin cancer oncogenesis. In a recent case-control
study, the prevalence of EV-HPV DNA in benign keratotic skin
lesions was equally high in organ transplant recipients with and
without a history of skin cancer, i.e. 55 and 53% in the two groups,
respectively (de Jong-Tieben et al, 2000) and the detection rate and
spectrum of HPV infection in hyperkeratotic papillomas, actinic
keratoses and squamous cell carcinomas is similar (Berkhout et al,
2000). The existence of one single or of a few oncogenic EV-HPV
types seems unlikely (Berkhout et al, 2000).
In addition, HPV DNA is not detectable in outgrowing cells
from explant cultures of malignant and premalignant skin lesions of
organ transplant recipients established at the air±liquid interface,
indicating that EV-HPV positive keratinocytes do not ef®ciently
proliferate in vitro, or HPV DNA is present in only a few basal cells,
making it improbable that these cells are located at the outgrowing
margins (Boxman et al, 2000).
In skin samples of patients with psoriasis and bullous diseases
HPV5 DNA can also frequently be detected (Favre et al, 1998;
Favre et al, 2000), and epidermal repair in patients with extensive
second-degree burns is associated with the generation of anti-
HPV5 antibodies (Favre et al, 2000). EV-HPV have also been
detected in recurrent cutaneous and mucosal lesions of a stoma-
carrier (Wieland et al, 1998). Therefore, the frequent presence of
EV-HPV in squamous cell carcinomas of organ transplant recipients
does not indicate that these HPV types are necessarily causatively
involved in cutaneous oncogenesis.
Recently, in the immunocompetent population no statistically
signi®cant differences could be detected between the presence of
HPV DNA in basal cell carcinomas and normal skin nor between
antibody prevalence in basal cell carcinoma patients and dermato-
logically healthy individuals (Wieland et al, 2000). This suggests that
the occurrence of human papillomavirus-DNA in basal cell
carcinoma does not re¯ect a major etiologic role of human
papillomavirus in this speci®c skin cancer in immunocompetent
hosts (Wieland et al, 2000).
INTERACTION BETWEEN EXPOSURE TO SUNLIGHT
AND EV-HPV INFECTION IN RELATION TO SKIN
CANCER
The oncogenic mechanisms of EV-HPV types remain uncertain in
contrast to those of the HPV types involved in anogenital
malignancy, but there appears to be a crucial additional require-
ment for UV radiation (Harwood et al, 1999a, b). A higher
prevalence of EV-HPV DNA was found in benign skin lesions
from sun-exposed sites, but only in patients with a history of skin
cancer (de Jong-Tieben et al, 2000).
Ultraviolet light may exert its harmful effect by inducing DNA
damage and/or by inducing local immunologic unresponsiveness
(Kripke, 1994). Sun exposure might directly activate functions of
HPV or sun exposure may enhance HPV replication in the host by
inducing (local) immunosuppression and/or inactivating of kera-
tinocyte growth regulating host genes (e.g., p53). In this respect it is
important to note that the E6 protein from a range of cutaneous
HPV types effectively inhibits apoptosis in response to UV damage
(Jackson and Storey, 2000). This occurs in both p53 null and wild-
type cells and does not require p53 degradation (Jackson and
Storey, 2000). As EV-HPV is widely distributed it can be
hypothesized that individuals who are infected by EV-HPV are
at an increased risk of developing solar keratoses and squamous cell
carcinomas by the inhibition of UV-induced apoptosis (Fig 3).
Figure 1. HPV in different skin lesions.
Percentages of HPV DNA in squamous cell
carcinomas (SCC), Bowen's disease (MB), basal
cell carcinomas (BCC), actinic keratoses (AK),
hyperkeratotic papillomas (HP), and normal skin
(NS) as tested with PCR that are speci®c for EV-
HPV types of subgroup A, B, and C, and other
cutaneous HPV types: S (for explanation, see
text). Modi®ed from Berkhout et al (2000).
Figure 2. Association between keratotic skin lesions and skin
cancer. Mean number of keratotic skin lesions in organ transplant
recipients with and without squamous cell carcinoma (SCC) and basal
cell carcinoma (BCC). Modi®ed from de Jong-Tieben et al (2000).
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Finally, it cannot be excluded that HPV infection by itself is not
a direct causative factor but, when present, it modi®es the risk of
UV-light induced skin cancer.
THE POSSIBLE ROLE OF P53 IN HPV-RELATED
ONCOGENESIS
The p53 tumor suppressor gene is a transcriptional activator
involved in the control of the cell cycle (Brash et al, 1991). Like in
the immunocompetent population, the high prevalence of p53
immunostaining in premalignant and malignant skin lesions of
organ transplant recipients supports a role for p53 protein in skin
cancer (McGregor et al, 1994, 1997; FerraÂndiz et al, 1999; Hudson
et al, 1999).
Degradation of the tumor suppressor gene p53 induced by the
E6 protein of genital oncogenic HPV types is also an important
mechanism for human papillomavirus-induced carcinogenesis
(Storey et al, 1998). A common genomic polymorphism occurs at
codon 72 of the p53 gene, and in vitro the codon 72 Arginine
variant appears to be particularly susceptible to degradation (Storey
et al, 1998). In a large study with organ transplant recipients,
however, the p53 codon 72 Arginine allele did not confer
susceptibility to the development of skin tumors after renal
transplantation (Marshall et al, 2000). Also in the immunocompe-
tent population no association was found between arginine
homozygosity of codon 72 in the p53 gene and the development
of cutaneous squamous cell carcinoma, basal cell carcinoma, or
malignant melanoma (Bastiaens et al, 2001). In accordance with this
observation it has been shown that the E6 protein of EV-HPV type
8 does not form a complex with p53 (Steger and P®ster, 1992).
SYNTHESIS/PROPOSED MECHANISM
It is conceivable that the development of squamous cell carcinomas
in organ transplant recipients is the result of a complex interplay
between EV-HPV infection, exposure to UV radiation, genetic
predisposition, immune response, and possibly other factors, such as
tobacco smoking, etc. The role of EV-HPV infection in the
development of skin cancer in this complex interplay is still unclear.
Although HPV infection may play a role in the development of
squamous cell carcinomas, its role in the development of basal cell
carcinomas remains highly speculative. HPV, no doubt, pro®t
considerably from immunosuppression, as is indicated by the large
number of warts in organ transplant recipients and, additionally,
these HPV may pro®t from UV-light-induced immunosuppres-
sion.
The equally high prevalence of EV-HPV infection in patients
with and without a history of skin cancer and the fact that, until
now, no high-risk oncogenic EV-HPV types could be identi®ed,
are arguments against a direct causative role of EV-HPV infection
in skin cancer oncogenesis and indicate that besides EV-HPV
infection, other factors, such as sun exposure, may be crucial.
We hypothesize that EV-HPV infection is a (possibly necessary)
cofactor in the complex interplay between environmental and
genetic factors causing cutaneous squamous cell carcinoma. In this
regard, inhibition of apoptosis in response to UV damage by the E6
protein from a range of cutaneous HPV types may play a key role in
providing a survival advantage to genetically damaged keratino-
cytes, which cells otherwise would have been destroyed by
apoptotic defense mechanisms.
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Zuuren, F.H.J. Claas, J.P. Vandenbroucke, R.G.J. Westendorp, H. P®ster, P.
Fuchs, L. Gissmann, L.M. de Jong-Tieben, R.J.M. Berkhout, H.L. Smits,
I.L.A. Boxman, R. Broer, I.R. Hardie, and A. Green for their contribution to
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